Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer01:27

Peptic Ulcer

30
Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the...
30
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

1.0K
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
1.0K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.5K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.5K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.1K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

787
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
787
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.7K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.

Journal of Crohn's & colitis·2022
Same author

Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Systematic Review and Meta-Analysis of Observational Studies.

Journal of clinical medicine·2022
Same author

Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.

Journal of Crohn's & colitis·2022
Same author

Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.

Journal of clinical medicine·2022
Same author

Empirical vs. Susceptibility-Guided Treatment of <i>Helicobacter pylori</i> Infection: A Systematic Review and Meta-Analysis.

Frontiers in microbiology·2022
Same author

Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of <i>Helicobacter</i><i>pylori</i> Infection (Hp-EuReg).

Journal of clinical medicine·2022

Related Experiment Video

Updated: Mar 31, 2026

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

439

[Helicobacter pylori-associated diseases].

Javier P Gisbert1

  • 1Servicio de Aparato Digestivo, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.

Gastroenterologia Y Hepatologia
|November 2, 2015
PubMed
Summary
This summary is machine-generated.

Helicobacter pylori infection remains prevalent, especially in developing nations, with rising antibiotic resistance. Current eradication therapies are often ineffective, necessitating novel treatment strategies for better patient outcomes.

Keywords:
ClarithromycinClaritromicinaCáncer gástricoDiagnosisDiagnósticoGastric cancerHelicobacter pyloriMetronidazolMetronidazoleResistanceResistenciaTratamientoTreatment

More Related Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

893
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 31, 2026

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

439
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

893
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

1.1K

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • Helicobacter pylori (H. pylori) infection prevalence is decreasing globally but remains high in developing countries.
  • Antibiotic resistance to clarithromycin, metronidazole, and quinolones is increasing worldwide.
  • H. pylori eradication reduces gastric cancer risk, but precancerous lesions increase risk even after successful eradication.

Purpose of the Study:

  • To summarize key findings on H. pylori infection from Digestive Disease Week 2015.
  • To review current H. pylori eradication therapies and their effectiveness.
  • To highlight challenges in H. pylori management and treatment resistance.

Main Methods:

  • Summary of studies presented at Digestive Disease Week 2015.
  • Analysis of H. pylori prevalence and antibiotic resistance patterns.
  • Evaluation of various H. pylori eradication treatment regimens.

Main Results:

  • Standard triple therapy for H. pylori eradication is increasingly ineffective.
  • Sequential therapy effectiveness is lower than initially reported; concomitant therapy is more effective.
  • Second-line therapies like levofloxacin-based quadruple therapy show high eradication rates (≥90%).
  • Newer quinolones and rifabutin-based rescue therapies offer options after treatment failures.
  • Management of H. pylori infection in Europe is heterogeneous with suboptimal eradication rates.

Conclusions:

  • H. pylori eradication is crucial but challenging due to rising resistance and declining therapy effectiveness.
  • Concomitant and second-line levofloxacin-based quadruple therapies are recommended over sequential therapy.
  • Novel agents and strategies are needed for difficult-to-eradicate H. pylori infections.
  • Addressing clinical practice variations and improving primary care management are essential.